Emerging drugs for schizophrenia

被引：18

作者：

Biedermann, Falko ^{[1
]}

Fleischhacker, W. Wolfgang ^{[1
]}

机构：

[1] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, Clin Biol Psychiat, A-6020 Innsbruck, Austria

来源：

EXPERT OPINION ON EMERGING DRUGS | 2011年 / 16卷 / 02期

关键词：

add-on treatment; adjunctive treatment; antipsychotic; combination treatment; drug; mechanism of action; schizophrenia; treatment; PLACEBO-CONTROLLED-TRIAL; SARCOSINE N-METHYLGLYCINE; DOPAMINE D-1 RECEPTOR; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; COGNITIVE IMPAIRMENTS; GALANTAMINE AUGMENTATION; ADJUNCTIVE TREATMENT; ANTIPSYCHOTIC-DRUGS; PSYCHOTIC DISORDERS;

D O I：

10.1517/14728214.2011.556112

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: With the focus on the topics mentioned above, the authors briefly review the latest clinical research organized on the basis of receptor systems and other drug targets, which are discussed to be involved in the pathophysiology of schizophrenia. Expert opinion: In conclusion, although clinicians will have to have considerable patience before truly novel anti-schizophrenia treatments become obtainable, a number of interesting leads with considerable theoretical potential are being explored. As yet, it is difficult to predict which of these mechanisms will effectively augment the currently available treatments.

引用

页码：271 / 282

页数：12

共 89 条

[1]

AGNOLI A, 1988, INT J CLIN PHARM RES, V8, P189

[2] Clozapine:: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a rosetta stone of antipsychotic drugs [J].

Ahlenius, S .

PHARMACOLOGY & TOXICOLOGY, 1999, 84 (05) :193-196

[3] Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial [J].

Akhondzadeh, Shahin ;

Tabatabaee, Maryam ;

Amini, Homayoun ;

Abhari, Seyed Ali Ahmadi ;

Abbasi, Seyed Hesamedin ;

Behnam, Behnaz .

SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) :179-185

[4] Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial [J].

Akhondzadeh, Shahin ;

Mohammadi, Neyousha ;

Noroozian, Maryam ;

Karamghadiri, Naregs ;

Ghoreishi, Aboulfazl ;

Jamshidi, Amir-Hossein ;

Forghani, Saeedeh .

SCHIZOPHRENIA RESEARCH, 2009, 107 (2-3) :206-212

[5] Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial [J].

Amminger, G. Paul ;

Schafer, Miriam R. ;

Papageorgiou, Konstantinos ;

Klier, Claudia M. ;

Cotton, Sue M. ;

Harrigan, Susan M. ;

Mackinnon, Andrew ;

McGorry, Patrick D. ;

Berger, Gregor E. .

ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (02) :146-154

[6] BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans [J].

Appel, Lieuwe ;

Geffen, Yona ;

Heurling, Kerstin ;

Eriksson, Catarina ;

Antoni, Gunnar ;

Kapur, Shitij .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (12) :841-850

[7] Muscarinic and nicotinic cholinergic agonists:: Structural analogies and discrepancies [J].

Bikádi, Z ;

Simonyi, M .

CURRENT MEDICINAL CHEMISTRY, 2003, 10 (23) :2611-2620

[8] Is Flunarizine a Long-Acting Oral Atypical Antipsychotic? A Randomized Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia [J].

Bisol, Luisa W. ;

Brunstein, Miriam G. ;

Ottoni, Gustavo L. ;

Ramos, Fernanda L. P. ;

Borba, Daniela L. ;

Daltio, Claudiane S. ;

de Oliveira, Ricardo V. ;

Paz, Gisele E. G. ;

de Souza, Sayuri E. ;

Bressan, Rodrigo A. ;

Lara, Diogo R. .

JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (10) :1572-1579

[9] Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data [J].

Black, MD .

PSYCHOPHARMACOLOGY, 2005, 179 (01) :154-163

[10]

BOSE A, 2010, 23 C EUR COLL NEUR A

← 1 2 3 4 5 6 7 8 9 →